Jul 16, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these advances …

SUMMARY Purpose The management of advanced prostate cancer is rapidly evolving. To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational …

The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades the standard of …

Apr 1, 2025 · This narrative collaborative review summarises the data behind combination treatment approaches for locally advanced prostate cancer (LAPC) and mHSPC, and discusses on-going …

Feb 10, 2026 · Traditionally, treatment of mCSPC was androgen deprivation therapy (ADT) until progression to castration-resistant prostate cancer (CRPC), at which stage alternative treatments …

This disproportionate impact of prostate cancer morbidity and mortality on Black men is an area of active investigation that includes new approaches to screening, access to care, and treatment …

Treatment of metastatic prostate cancer is generally based on whether its growth can be slowed or stopped with hormone therapy. Recall that testosterone (an androgen hormone) is the “fuel” that …

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) What You Should Know What is Advanced Prostate Cancer? When prostate cancer spreads beyond the prostate or returns after treatment, it is …

The treatment landscape of advanced prostate cancer continues to evolve, particularly over the last 5+ years. Although there are several treatment options, including both ADT-based doublet and triplet …

Mar 20, 2023 · Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer …